Presentation is loading. Please wait.

Presentation is loading. Please wait.

Activity limitation scores across the 71 patients with PAVMs in the study cohort. Activity limitation scores across the 71 patients with PAVMs in the study.

Published byEmil Scholz Modified over 5 years ago

Similar presentations

Presentation on theme: "Activity limitation scores across the 71 patients with PAVMs in the study cohort. Activity limitation scores across the 71 patients with PAVMs in the study."— Presentation transcript:

1 Activity limitation scores across the 71 patients with PAVMs in the study cohort.
Activity limitation scores across the 71 patients with PAVMs in the study cohort. VSAQ scores (for men, women and combined) were denoted by the lowest number/first activity when a patient would typically have to stop (for details across the 1–13 VSAQ scale, see figure 1). These were approximated to the MRC Dyspnoea Scale and NYHA classification as indicated. MRC, Medical Research Council; NYHA, New York Heart Association; PAVM, pulmonary arteriovenous malformation; VASQ, Veterans Specific Activity Questionnaire. Filip Gawecki et al. BMJ Open Resp Res 2019;6:e000351 ©2019 by British Thoracic Society

Download ppt "Activity limitation scores across the 71 patients with PAVMs in the study cohort. Activity limitation scores across the 71 patients with PAVMs in the study."

Similar presentations

Visual analogue scale (VAS) for pain on different procedures.

Visual analogue scale (VAS) for pain on different procedures.
The significantly different metabolites between the systemic inflammatory response syndrome SIRS (n=15) and sepsis (n=35) groups (A); the sepsis (n=10)

The significantly different metabolites between the systemic inflammatory response syndrome SIRS (n=15) and sepsis (n=35) groups (A); the sepsis (n=10)
Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.

Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.
(A) Changes in plaque and gingival index (Silness and Löe)21 for patients 1–8 over a 7-day period using oral hygiene intervention either with a toothbrush.

(A) Changes in plaque and gingival index (Silness and Löe)21 for patients 1–8 over a 7-day period using oral hygiene intervention either with a toothbrush.
Image of the form used by ambulance officers to triage patients with an exacerbation of chronic obstructive pulmonary disease (COPD).  GP, general practitioner;

Image of the form used by ambulance officers to triage patients with an exacerbation of chronic obstructive pulmonary disease (COPD).  GP, general practitioner;
Patients with exacerbations of chronic obstructive pulmonary disease admitted to hospital according to the day of the week (A), and presenting to the emergency.

Patients with exacerbations of chronic obstructive pulmonary disease admitted to hospital according to the day of the week (A), and presenting to the emergency.
The top 25 analytes by relevant q-value differentially expressed in HIV with COPD. The top number is m/z and the bottom number is RT. Y-axis is intensity.

The top 25 analytes by relevant q-value differentially expressed in HIV with COPD. The top number is m/z and the bottom number is RT. Y-axis is intensity.
Evolution of pulmonary arteriovenous malformations (PAVMs) evidence base since 1945. a) Types of articles. Evolution of pulmonary arteriovenous malformations.

Evolution of pulmonary arteriovenous malformations (PAVMs) evidence base since a) Types of articles. Evolution of pulmonary arteriovenous malformations.
For most patients with asthma airway response becomes flatter after 1000 µg of inhaled corticosteroid, but systemic activity (measured by serum cortisol.

For most patients with asthma airway response becomes flatter after 1000 µg of inhaled corticosteroid, but systemic activity (measured by serum cortisol.
Association of sputum colour score with (A) total cell counts; (B) neutrophil proportion; (C) neutrophil number and (D) CXCL-8 concentration. Association.

Association of sputum colour score with (A) total cell counts; (B) neutrophil proportion; (C) neutrophil number and (D) CXCL-8 concentration. Association.
Serum levels of angiopoietin-like protein 4 (ANGPTL4) according to patients with chronic obstructive pulmonary disease and controls without any lung disease.

Serum levels of angiopoietin-like protein 4 (ANGPTL4) according to patients with chronic obstructive pulmonary disease and controls without any lung disease.
Change from baseline in (A) E-RS total score and (B) E-RS cough and sputum domain score over the study period in ATTAIN and the active-comparator study.

Change from baseline in (A) E-RS total score and (B) E-RS cough and sputum domain score over the study period in ATTAIN and the active-comparator study.
Percentage of patients per stage of oesophageal cancers in the two trials, overall difference P

Percentage of patients per stage of oesophageal cancers in the two trials, overall difference P
Sample figures of typical bronchoscopy findings illustrating the effect of i-scan image enhancement technique and differences in vascular patterns. Sample.

Sample figures of typical bronchoscopy findings illustrating the effect of i-scan image enhancement technique and differences in vascular patterns. Sample.
Comparison of the age-associated prevalence (y axis) in the Catalan Healthcare Surveillance System (CHSS) and Medicare datasets of selected disease groups.

Comparison of the age-associated prevalence (y axis) in the Catalan Healthcare Surveillance System (CHSS) and Medicare datasets of selected disease groups.
Change from baseline in the severity of night-time cough and the frequency of night-time sputum production at week 12 in ACCORD COPD I.17 Data are reported.

Change from baseline in the severity of night-time cough and the frequency of night-time sputum production at week 12 in ACCORD COPD I.17 Data are reported.
Level of physical activity by Global Initiative for Obstructive Lung Disease (GOLD) stage, BODE (body mass index, FEV1 for airflow obstruction, dyspnoea,

Level of physical activity by Global Initiative for Obstructive Lung Disease (GOLD) stage, BODE (body mass index, FEV1 for airflow obstruction, dyspnoea,
Occurrence of morning symptoms

Occurrence of morning symptoms
Prevalence (x axis) of disease groups (DGs) (y axis) in the population of Medicare (light cyan) and Catalan Healthcare Surveillance System (CHSS) (light.

Prevalence (x axis) of disease groups (DGs) (y axis) in the population of Medicare (light cyan) and Catalan Healthcare Surveillance System (CHSS) (light.
Comparison of the bronchoalveolar lavage fluid (BALF) levels of the three vascular endothelial growth factor (VEGF) types in healthy volunteers and patients.

Comparison of the bronchoalveolar lavage fluid (BALF) levels of the three vascular endothelial growth factor (VEGF) types in healthy volunteers and patients.

Similar presentations

Ads by Google